Shares of Moderna Inc (NASDAQ:MRNA) have been assigned a consensus recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $26.30.

MRNA has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Moderna in a research note on Monday, August 12th. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Moderna in a research note on Sunday, June 2nd. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Moderna in a research note on Sunday, August 11th. Morgan Stanley set a $30.00 price objective on shares of Moderna and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Oppenheimer increased their target price on shares of Moderna from $27.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 29th.

NASDAQ:MRNA traded down $1.17 during mid-day trading on Friday, reaching $15.92. The stock had a trading volume of 3,403,125 shares, compared to its average volume of 1,242,477. The company has a market cap of $5.74 billion and a PE ratio of -3.22. The company has a 50 day moving average of $14.10. Moderna has a fifty-two week low of $11.54 and a fifty-two week high of $29.79.

Moderna (NASDAQ:MRNA) last posted its earnings results on Wednesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.01. The business had revenue of $13.08 million during the quarter, compared to analyst estimates of $18.80 million. On average, analysts predict that Moderna will post -1.62 EPS for the current year.

About Moderna

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

See Also: Investing in Blue-Chip Stocks

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with's FREE daily email newsletter.